-29.4%
AXON vs GSK
+31.2%
-60.6%
-55.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -4.2% | -1.9% | -2.3% | -4.3% |
| 7D | -14.2% | -1.8% | -12.3% | -14.3% |
| 30D | -15.4% | -2.2% | -13.2% | -15.5% |
| 3M | +0.5% | -1.8% | +2.3% | +0.6% |
| 6M | -9.5% | -10.6% | +1.1% | -10.9% |
| YTD | -9.2% | +4.4% | -13.6% | -10.3% |
| 1Y | -29.4% | +30.4% | -59.8% | -29.8% |
| All | -29.4% | +31.2% | -60.6% | -29.8% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling